C4A and infection: Here, we evaluated the therapeutic efficacy of a vaccine candidate formulated with TSA-1-C4 + Tc24-C4 recombinant antigens combined with a 4-fold reduction in the amount and dosage regimen of BNZ treatment given during the early chronic phase of T. cruzi-infection in a murine model and followed until the late chronic phase of the disease.